News

The company expects to make the updated Spikevax available to U.S. patients in time for the 2025-26 respiratory virus season.
Arexvy is currently approved for use in all individuals aged 60 and older, as well as for high-risk individuals aged 50-59.
The label expansion sought by GSK is a bid to compete with Pfizer and Moderna in the younger age groups of the RSV vaccine market. Pfizer’s Abrysvo and Moderna’s mRESVIA are both approved to prevent ...
A court battle between Regeneron and Amgen is testing the legal limits of how far drugmakers can go in using patents to ...